SHH · 688319.SS
Chengdu Olymvax Biopharmaceuticals Inc.
CN¥26.28+CN¥0.87 (+3.42%)
Chengdu Olymvax Biopharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 41.47% below the high.
Loading market information…
SHH · 603590.SS · CNY
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 07:00 AM UTC. Cached market data; not a live quote.
One-year closing-price history · CNY. Historical prices are not a forecast.
Beijing Konruns Pharmaceutical Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 51.12% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Beijing Konruns Pharmaceutical Co.,Ltd.’s forward annual dividend is CN¥0.35 per share, paid annual. The forward yield is 1.41% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Beijing Konruns Pharmaceutical Co.,Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Beijing Konruns Pharmaceutical Co.,Ltd., a Chinese company established in 2003 and based in Beijing, focuses on the discovery, production, and distribution of various pharmaceutical items. Among its key offerings is Su Ling, a hemagglutinin preparation designed to minimize blood loss during surgical procedures and manage post-operative bleeding. The firm is also actively developing a pipeline of potential new medicines, such as CX1026, CX1003, and KC1036.
Latest available per-share figures in CNY. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 09:27 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CN¥26.28+CN¥0.87 (+3.42%)
Chengdu Olymvax Biopharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 41.47% below the high.
CN¥14.98+CN¥1.36 (+9.99%)
Guilin Sanjin Pharmaceutical Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 4.89% below the high.
CN¥7.27+CN¥0.06 (+0.83%)
Zhejiang Ausun Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 32.75% below the high.
CN¥37.84+CN¥0.31 (+0.83%)
Hangzhou Biotest Biotech Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 25.77% below the high.
CN¥3.07+CN¥0.16 (+5.5%)
Guizhou Xinbang Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 26.02% below the high.
CN¥11.14-CN¥0.07 (-0.62%)
Wuhan Keqian Biology Co.,Ltd’s quoted price sits in the lower half of its reported 52-week range, 37.45% below the high.
CN¥10.10-CN¥0.04 (-0.39%)
Hunan Jiudian Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 41.85% below the high.
CN¥14.65-CN¥0.58 (-3.81%)
Anhui Huaheng Biotechnology Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 66.4% below the high.
